Department of Pharmacoepidemiology, Kyoto University, Kyoto, Japan
Department of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Katushika-ku, Tokyo, Japan.
BMJ Open. 2023 Jul 30;13(7):e070417. doi: 10.1136/bmjopen-2022-070417.
Concerns about public health threats have shifted towards obesity-related, non-communicable diseases in both developed and developing countries. Since 2008, Japan has adopted a nationwide universal screening programme called Specific Health check-ups (SHC) for the primary prevention of obesity-related, non-communicable diseases, namely, diabetes, hypertension and hyperlipidaemia. The effectiveness of SHC has not been systemically evaluated to date.
We will use the employment-based health insurance database, which includes both records of receipt versus non-receipt of SHC and healthcare claims. The study design adopts the target trial emulation framework to minimise the bias inherent to the observational study (eg, time-related bias and its consequences). The key components of trial emulation-eligibility criteria, treatment strategy, assignment procedure, follow-up period, outcome, causal contrast of interest and analysis plan-are detailed, along with the ideal target trial protocol. Briefly, we will conduct the nested-trial emulation approach that allows multiple trial entries. Persons aged 40-74 years will be eligible if they do not have a documented diagnosis of hypertension and diabetes and a history of receiving SHC at baseline. Participants will be classified according to the receipt or non-receipt of SHC service and followed for a maximum of 10 years until the withdrawal from the insurance plan, the outcome occurrence or the administrative censoring (the end of the available data, expected to be March 2022), whichever comes first. The 10-year incidence of diabetes/hypertension will be compared between SHC recipients and non-recipients using pooled logistic regression with adjustments for baseline confounders. Five sensitivity analyses are employed, including per-protocol analysis, changing eligibility criteria and negative outcome control analysis.
This protocol obtained the approval from Kyoto University Graduate School and Faculty of Medicine, Ethics Committee (R2448). The findings will be disseminated to academic conferences, and published in a peer-reviewed journal.
在发达国家和发展中国家,公众健康威胁的关注点已转向与肥胖相关的非传染性疾病。自 2008 年以来,日本实施了一项全国性的普遍筛查计划,称为特定健康检查(SHC),以预防肥胖相关的非传染性疾病,包括糖尿病、高血压和高脂血症。迄今为止,尚未系统评估 SHC 的效果。
我们将使用基于就业的健康保险数据库,其中包括接受和未接受 SHC 筛查的记录以及医疗保健索赔。研究设计采用目标试验模拟框架,以最大限度地减少观察性研究固有的偏倚(例如,时间相关偏倚及其后果)。试验模拟的关键组成部分-资格标准、治疗策略、分配程序、随访期、结局、感兴趣的因果对比和分析计划-都进行了详细说明,并附有理想的目标试验方案。简而言之,我们将进行嵌套试验模拟方法,允许多次试验进入。年龄在 40-74 岁之间的人员,如果在基线时没有高血压和糖尿病的记录诊断且没有接受过 SHC,则有资格参加。参与者将根据是否接受 SHC 服务进行分类,并随访最长 10 年,直到退出保险计划、出现结局或行政删失(可用数据结束,预计为 2022 年 3 月),以先发生者为准。使用调整基线混杂因素的汇总逻辑回归,比较 SHC 接受者和非接受者的 10 年糖尿病/高血压发生率。进行了 5 项敏感性分析,包括方案分析、改变资格标准和阴性结局控制分析。
本方案已获得京都大学研究生院和医学院伦理委员会(R2448)的批准。研究结果将在学术会议上进行传播,并发表在同行评议的期刊上。